Lumosa Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

Lumosa Therapeutics 의 총 주주 지분은 NT$1.2B 이고 총 부채는 NT$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 NT$1.4B 및 NT$201.2M 입니다.

주요 정보

부채 비율

NT$0

부채

이자 보상 비율	n/a
현금	NT$555.62m
주식	NT$1.18b
총 부채	NT$201.24m
총 자산	NT$1.38b

최근 재무 상태 업데이트

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24

Recent updates

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Mar 10

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24

재무 상태 분석

단기부채: 6535 의 단기 자산 ( NT$733.5M )이 단기 부채( NT$195.9M ).

장기 부채: 6535 의 단기 자산( NT$733.5M )이 장기 부채( NT$5.3M ).

부채 대 자본 내역 및 분석

부채 수준: 6535 부채가 없습니다.

부채 감소: 6535 지난 5년간 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 6535 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: 6535 14.4 1.9 14.4 % 매년.

Lumosa Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Lumosa Therapeutics Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lumosa Therapeutics Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001, A Novel Treatment for Acute Ischemic Stroke, in UK

Now 18% overvalued after recent price rise

Now 22% overvalued after recent price rise

Less than half of directors are independent

Less than half of directors are independent

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 50 million in funding

Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson

Lumosa Therapeutics Co., Ltd. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: NT$1.47 loss per share (vs NT$3.05 loss in FY 2022)

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 02, 2024

Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke

New minor risk - Share price stability

Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001

Second quarter 2023 earnings released: NT$0.92 loss per share (vs NT$1.20 loss in 2Q 2022)

Full year 2022 earnings released: NT$3.05 loss per share (vs NT$0.64 profit in FY 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: NT$1.20 loss per share (vs NT$0.74 loss in 2Q 2021)

First quarter 2022 earnings released: NT$1.14 loss per share (vs NT$0.46 profit in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 24, 2022

Lumosa Therapeutics Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces Lt3001 Granted Fast TrackDesignation for the Treatment of Acute Ischemic Stroke Toexpedite the Drug Registration Process with the US FDA

Lumosa Announces the Completion of the Phase 1Clinical Trial on the Pharmacokinetics of Multiple Dosesand the Drug-Drug Interaction for LT3001

Lumosa Receives an Notification from AMed Regarding the Receipt of an Import Permit from Thai Food and Drug Administration for Naldebain

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 330 million in funding

Investor sentiment improved over the past week

Second quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.67 loss in 2Q 2020)

Lumosa Therapeutics Co., Ltd. Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces the Granting of the Formulation Patent for LT1001

Patent of Lumosa’s LT5001 Product Granted by Taiwan Intellectual Property Office

First quarter 2021 earnings released: EPS NT$0.46 (vs NT$0.95 loss in 1Q 2020)

Chief Internal Auditor has left the company

Full year 2020 earnings released: NT$2.67 loss per share (vs NT$2.05 loss in FY 2019)

Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 99.992 million in funding from Far Glory Life Insurance Co., Ltd., Asset Management Arm

Lumosa Therapeutics Co., Ltd. Announces Resignation of Ya-Ting Hsu as Chief Internal Auditor, Effective March 31, 2021

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Lumosa Therapeutics Co., Ltd. Announces Approval by Korean Intellectual Property Office and European Patent Office for Lumosa's LT3001, A New Drug for Acute Ischemic Stroke

New 90-day low: NT$33.45

Lumosa Therapeutics Receives Market Approval of LT001 from Singapore's Health Science Agency

Lumosa Therapeutics Co., Ltd. to Commence A Multi-Dose,Drug-Drug-Interaction, Phase I Trial of LT3001 for AIS

Lumosa Announces Completion of Enrollment Inphase 2 Clinical Trial of Its LT3001 for Thetreatment of Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 855.5 million in funding from Center Laboratories, Inc. and other investors

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Third quarter 2020 earnings released: NT$0.40 loss per share

New 90-day low: NT$33.90

Lumosa and AMed Sign a Supplementary Licensing Agreement for the Licensing of Extended-Release Analgesic Injection in Southeast Asia

First half earnings released

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기